Immuneering (IMRX) News Today $6.50 +0.39 (+6.38%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$6.60 +0.10 (+1.54%) As of 10/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMRX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Insider Buying: Immuneering (NASDAQ:IMRX) Director Purchases 7,500 Shares of StockOctober 7 at 12:36 PM | marketbeat.comImmuneering Corporation (NASDAQ:IMRX) Short Interest Up 61.7% in SeptemberOctober 6 at 2:26 PM | marketbeat.comBrokerages Set Immuneering Corporation (NASDAQ:IMRX) Target Price at $17.75October 2, 2025 | americanbankingnews.comImmuneering (IMRX) Price Target Increased by 29.69% to 16.93October 1, 2025 | msn.comImmuneering Corporation Stock (IMRX) Opinions on Public Offering and Clinical DataOctober 1, 2025 | quiverquant.comQImmuneering (NASDAQ:IMRX) Director Purchases $52,725.00 in StockOctober 1, 2025 | marketbeat.comImmuneering (NASDAQ:IMRX) Given Buy Rating at HC WainwrightOctober 1, 2025 | americanbankingnews.comPositive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX)September 30, 2025 | insidermonkey.comPeter Feinberg Acquires 5,000 Shares of Immuneering (NASDAQ:IMRX) StockSeptember 30, 2025 | marketbeat.comImmuneering (NASDAQ:IMRX) Given "Buy" Rating at HC WainwrightSeptember 30, 2025 | marketbeat.comImmuneering Corporation (IMRX) Discusses Phase 2a Data Update For IMM-1-104 In First-Line Pancreatic Cancer (Transcript)September 29, 2025 | seekingalpha.comImmuneering Corporation - Special CallSeptember 29, 2025 | seekingalpha.comImmuneering Corporation (NASDAQ:IMRX) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 29, 2025 | marketbeat.comFlower City Capital Makes New Investment in Immuneering Corporation $IMRXSeptember 27, 2025 | marketbeat.comChardan Capital Maintains Immuneering (IMRX) Buy RecommendationSeptember 26, 2025 | msn.comImmuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday ...September 26, 2025 | markets.businessinsider.comImmuneering Corporation to Host Conference Call on Updated Survival Data for Pancreatic Cancer TreatmentSeptember 26, 2025 | quiverquant.comQImmuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025September 26, 2025 | globenewswire.comImmuneering (NASDAQ:IMRX) Stock Price Expected to Rise, Chardan Capital Analyst SaysSeptember 26, 2025 | marketbeat.comImmuneering price target raised to $30 from $21 at OppenheimerSeptember 25, 2025 | msn.comImmuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 CatalystSeptember 25, 2025 | seekingalpha.comOppenheimer Forecasts Strong Price Appreciation for Immuneering (NASDAQ:IMRX) StockSeptember 25, 2025 | marketbeat.comImmuneering announces data from trial of atebimetinib combinationSeptember 25, 2025 | msn.comImmuneering announces Class A common stock offering, private placementSeptember 25, 2025 | msn.comImmuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to SanofiSeptember 24, 2025 | globenewswire.comImmuneering stock soars after reporting 86% survival rate in cancer trialSeptember 24, 2025 | za.investing.comImmuneering Corporation Reports Promising Survival Data for Atebimetinib in Pancreatic Cancer PatientsSeptember 24, 2025 | quiverquant.comQImmuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to SanofiSeptember 24, 2025 | globenewswire.comImmuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnPSeptember 24, 2025 | globenewswire.comImmuneering appoints Schall as Chairman of the BoardSeptember 17, 2025 | msn.comNeedham & Company LLC Boosts Immuneering (NASDAQ:IMRX) Price Target to $11.00September 16, 2025 | marketbeat.comImmuneering Appoints Dr. Thomas Schall as Chairman of the BoardSeptember 16, 2025 | globenewswire.comImmuneering to announce updated data from Phase 2a trial of Atebimetinib + mGnPSeptember 10, 2025 | msn.comImmuneering Corporation to Host Investor Call and Present Updated Data at Upcoming Scientific ConferencesSeptember 10, 2025 | quiverquant.comQImmuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25September 10, 2025 | globenewswire.comImmuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 6, 2025 | marketbeat.comPleasing Signs As A Number Of Insiders Buy Immuneering StockSeptember 5, 2025 | finance.yahoo.comImmuneering files to sell 9.18M shares of Class A common stock for holdersSeptember 3, 2025 | msn.comImmuneering (NASDAQ:IMRX) Receives "Buy" Rating from Needham & Company LLCAugust 28, 2025 | marketbeat.comImmuneering Corporation: Ripping On A Questionable CatalystAugust 26, 2025 | seekingalpha.comImmuneering Corporation Closes $25 Million Private Placement to Support Oncology Drug DevelopmentAugust 26, 2025 | quiverquant.comQImmuneering Announces Closing of $25 Million Private PlacementAugust 26, 2025 | globenewswire.comImmuneering signs supply deal with Lilly to test atebimetinib plus olomorasibAugust 25, 2025 | msn.comImmuneering stock soars on clinical supply deal with Eli LillyAugust 25, 2025 | za.investing.comImmuneering Inks Supply Agreement With Eli Lilly For Latter’s Investigational Cancer Therapy: Retail Looks To Buy The Stock On DipsAugust 25, 2025 | msn.comImmuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with OlomorasibAugust 25, 2025 | globenewswire.comImmuneering prices 6.3M shares at $3.95 in private placementAugust 22, 2025 | msn.comImmuneering Secures $25 Million in Private Placement to Advance Cancer Drug DevelopmentAugust 22, 2025 | msn.comImmuneering Corporation Announces $25 Million Private Placement Financing to Support Development of Innovative Cancer TreatmentsAugust 21, 2025 | quiverquant.comQImmuneering Announces $25 Million Private PlacementAugust 21, 2025 | globenewswire.com Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMRX Media Mentions By Week IMRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMRX News Sentiment▼1.330.63▲Average Medical News Sentiment IMRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMRX Articles This Week▼53▲IMRX Articles Average Week Get the Latest News and Ratings for IMRX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Immuneering and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ARDX News STOK News XERS News ZYME News AMLX News SION News TLRY News PHVS News AMPH News EVO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMRX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
